Comparative Efficacy of Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-analysis

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2022 Jun 30

PMID 35772597

Authors

Ayobami Akenroye

Grace Lassiter

John W Jackson

Corinne Keet

Jodi Segal

G Caleb Alexander

Hwanhee Hong

Affiliations

Soon will be listed here.

Abstract

Background: The comparative safety and efficacy of the biologics currently approved for asthma are unclear.

Objective: We compared the safety and efficacy of mepolizumab, benralizumab, and dupilumab in individuals with severe eosinophilic asthma.

Methods: We performed a systematic review of peer-reviewed literature published 2000 to 2021. We studied Bayesian network meta-analyses of exacerbation rates, prebronchodilator FEV, the Asthma Control Questionnaire, and serious adverse events in individuals with eosinophilic asthma.

Results: Eight randomized clinical trials (n = 6461) were identified. We found in individuals with eosinophils ≥300 cells/μL the following: in reducing exacerbation rates compared to placebo: dupilumab (risk ratio [RR], 0.32; 95% credible interval [CI], 0.23 to 0.45), mepolizumab (RR, 0.37; 95% CI, 0.30 to 0.45), and benralizumab (RR, 0.49; 95% CI, 0.43 to 0.55); in improving FEV: dupilumab (mean difference in milliliters [MD] 230; 95% CI, 160 to 300), benralizumab (MD, 150; 95% CI, 100 to 200), and mepolizumab (MD, 150; 95% CI, 66 to 220); and in reducing Asthma Control Questionnaire scores: mepolizumab (MD, -0.63; 95% CI, -0.81 to -0.45), dupilumab (MD, -0.48; 95% CI, -0.83 to -0.14), and benralizumab (MD, -0.32; 95% CI, -0.43 to -0.21). In individuals with eosinophils 150-299 cells/μL, benralizumab (RR, 0.62; 95% CI, 0.52 to 0.73) and dupilumab (RR, 0.60; 95% CI, 0.38 to 0.95) were associated with lower exacerbation rates; and only benralizumab (MD, 81; 95% CI, 8 to 150) significantly improved FEV. These differences were minimal compared to clinically important thresholds. For serious adverse events in the overall population, mepolizumab (odds ratio, 0.67; 95% CI, 0.48 to 0.92) and benralizumab (odds ratio, 0.74; 95% CI, 0.59 to 0.93) were associated with lower odds of a serious adverse event, while dupilumab was not different from placebo (odds ratio, 1.0; 95% CI, 0.74 to 1.4).

Conclusion: There are minimal differences in the efficacy and safety of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma.

Citing Articles

Single-center off-label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy.

Veltman Y, Aalbers A, Hermans M, Mutsaers P EJHaem. 2025; 6(1):e1014.

PMID: 39866927 PMC: 11756971. DOI: 10.1002/jha2.1014.

Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma.

Menzella F, Marchi M, Caminati M, Romagnoli M, Micheletto C, Bonato M J Clin Med. 2025; 14(1.

PMID: 39797273 PMC: 11722057. DOI: 10.3390/jcm14010191.

Successful novel use of dupilumab for gastrointestinal involvement of idiopathic hypereosinophilic syndrome: case report and review of the literature.

Moffatt C, Soriano C, Dawson D, Weiss G Clin J Gastroenterol. 2024; 17(6):1003-1008.

PMID: 39261360 DOI: 10.1007/s12328-024-02036-4.

Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics.

Nopsopon T, Brown A, Hahn G, Rank M, Huybrechts K, Akenroye A Respir Med. 2024; 234:107802.

PMID: 39260678 PMC: 11588503. DOI: 10.1016/j.rmed.2024.107802.

Comparative efficacy of biologics for patients with inadequately controlled asthma: A network meta-analysis.

Kim H, Kim M, Kim S, Lee J, Byun Y, Park J World Allergy Organ J. 2024; 17(7):100934.

PMID: 39091592 PMC: 11293571. DOI: 10.1016/j.waojou.2024.100934.

References

Viswanathan R, Busse W . How to compare the efficacy of biologic agents in asthma. Ann Allergy Asthma Immunol. 2020; 125(2):137-149. DOI: 10.1016/j.anai.2020.04.031. View

Juniper E, Svensson K, Mork A, Stahl E . Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005; 99(5):553-8. DOI: 10.1016/j.rmed.2004.10.008. View

Farne H, Wilson A, Powell C, Bax L, Milan S . Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017; 9:CD010834. PMC: 6483800. DOI: 10.1002/14651858.CD010834.pub3. View

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

McGregor M, Krings J, Nair P, Castro M . Role of Biologics in Asthma. Am J Respir Crit Care Med. 2018; 199(4):433-445. PMC: 6835092. DOI: 10.1164/rccm.201810-1944CI. View

Assaf S, Hanania N . Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019; 19(4):379-386. DOI: 10.1097/ACI.0000000000000549. View

Ramonell R, Iftikhar I . Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis. Lung. 2020; 198(1):95-103. PMC: 9136642. DOI: 10.1007/s00408-019-00310-8. View

Edris A, De Feyter S, Maes T, Joos G, Lahousse L . Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019; 20(1):179. PMC: 6688359. DOI: 10.1186/s12931-019-1138-3. View

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B . Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016; 388(10039):31-44. DOI: 10.1016/S0140-6736(16)30307-5. View

10.

Sullivan S, Rasouliyan L, Russo P, Kamath T, Chipps B . Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007; 62(2):126-33. DOI: 10.1111/j.1398-9995.2006.01254.x. View

11.

Ortega H, Yancey S, Mayer B, Gunsoy N, Keene O, Bleecker E . Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7):549-556. DOI: 10.1016/S2213-2600(16)30031-5. View

12.

Chupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L . Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017; 5(5):390-400. DOI: 10.1016/S2213-2600(17)30125-X. View

13.

Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K . Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26):2486-2496. DOI: 10.1056/NEJMoa1804092. View

14.

Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M . Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020; 29(156). PMC: 9488652. DOI: 10.1183/16000617.0137-2019. View

15.

Busse W, Chupp G, Nagase H, Albers F, Doyle S, Shen Q . Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol. 2018; 143(1):190-200.e20. DOI: 10.1016/j.jaci.2018.08.031. View

16.

Ortega H, Liu M, Pavord I, Brusselle G, FitzGerald J, Chetta A . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198-207. DOI: 10.1056/NEJMoa1403290. View

17.

Iftikhar I, Schimmel M, Bender W, Swenson C, Amrol D . Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis. Lung. 2018; 196(5):517-530. DOI: 10.1007/s00408-018-0151-5. View

18.

Oykhman P, Paramo F, Bousquet J, Kennedy D, Brignardello-Petersen R, Chu D . Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol. 2021; 149(4):1286-1295. DOI: 10.1016/j.jaci.2021.09.009. View

19.

Akenroye A, Heyward J, Keet C, Alexander G . Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals. J Allergy Clin Immunol Pract. 2021; 9(11):3969-3976. PMC: 8549114. DOI: 10.1016/j.jaip.2021.01.039. View

20.

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View